Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects aged 18 to 65 years (inclusive)~* Body mass index (weight \[kg\]/height \[m²\]) ≥30 and ≤45 kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45 kg/m² for subjects with controlled hypertension and/or dyslipidemia~* Non-smoker and had not used tobacco or nicotine products for at least 6 months before screening~* Normotensive (systolic ≤140 mm Hg and diastolic ≤90 mm Hg). Anti-hypertensive medications were allowed with the exception of alpha-adrenergic blockers, beta-blockers, and clonidine. Medical regimen was to be stable for at least 8 weeks.~* Low-density lipoprotein level \<190 mg/dL and triglycerides level \<400 mg/dL. Medications for the treatment of dyslipidemia were allowed as long as the medical regimen had been stable for at least 8 weeks.~* No clinically significant abnormality of serum albumin, blood urea nitrogen (BUN), creatinine, bilirubin, calcium and phosphorus~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 times upper limit of normal (ULN)~* No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC differential, or platelets~* Fasting glucose ≤126 mg/dL and not receiving hypoglycemic agents~* No clinically significant abnormality on urinalysis~* Thyroid stimulating hormone (TSH) within 1.5 times ULN or normal triiodothyronine (T3), if TSH was below normal limits~* Female subjects of childbearing potential had a negative serum pregnancy test~* An IDS-SR score \<2 on individual items: 5 (sadness), 6 (irritability), 7 (anxiety/tension), and 18 (suicidality) and an IDS-SR total score \<30~* Female subjects of childbearing potential were non-lactating and agreed to continue to use effective contraception throughout the study and 30 days after discontinuation of study drug~* Completed a food diary for 6 of 7 consecutive days during screening~* Able to comply with all required study procedures and schedule~* Able to speak and read English~* Provided written informed consent~Exclusion Criteria:~* Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established polycystic ovary syndrome)~* Serious medical condition (including but not limited to renal or hepatic insufficiency; congestive heart failure, angina pectoris, myocardial infarction, stroke, claudication, or acute limb ischemia; history of malignancy with exception of non-melanoma skin cancer or surgically cured cervical cancer)~* Serious psychiatric illness (e.g., lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder, e.g., borderline; severe major depressive disorder, recent \[previous 6 months\] suicide attempt or current active suicidal ideation, recent hospitalization due to psychiatric illness)~* Response to the bipolar disorder questions that indicated the presence of bipolar disorder.~* Required medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months~* History of drug or alcohol abuse or dependence within 1 year~* Type I or Type II diabetes mellitus~* Baseline ECG with a corrected QT (QTc) interval (using Bazett's formula \>450 millisecond (msec) \[males\] and \>470 msec \[females\]) or the presence of any clinically significant cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities~* Received excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer or anticonvulsant agents) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia; any anorectic or weight loss agents; any over-the-counter dietary supplements with psychoactive, appetite or weight effects; alpha-adrenergic blockers; beta-blockers; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids; topiramate, Depo-Provera®; smoking cessation agents; regular use of opioid or opioid-like analgesics~* History of surgical or device (e.g., lap band) intervention for obesity~* History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with \>5 minutes loss of consciousness, concussion symptoms lasting \>15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures)~* History of treatment with bupropion or naltrexone within the preceding 12 months~* History of hypersensitivity or intolerance to bupropion or naltrexone~* Used drugs, herbs, or dietary supplements believed to significantly affect body weight or participated in a weight loss management program within one month prior to baseline~* Loss or gained \>4.0 kilograms within the previous 3 months~* Females who were pregnant or breast-feeding or planning to become pregnant during the study period or within 30 days of discontinuing study drug~* Planned surgical procedure that could impact the conduct of the study~* Received any investigational drug or used an experimental device or procedure within the previous 30 days~* Participated in any previous clinical trial conducted by Orexigen~* Had any condition that in the opinion of the investigator made the subject unsuitable for inclusion into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NB32 (Type: EXPERIMENTAL): Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
- Placebo (Type: PLACEBO_COMPARATOR): Placebo with intensive group lifestyle modification counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).